deltatrials
Completed PHASE2/PHASE3 NCT00639327

Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

Randomized Phase II/III Trial of Second Line Chemotherapy Comparing CPT-11 Monotherapy Versus S-1/CPT-11 Combination for S-1 Refractory Gastric Cancer

Sponsor: Japan Clinical Cancer Research Organization

Conditions Gastric Cancer
Interventions S-1 + irinotecan irinotecan
Updated 6 times since 2017 Last updated: Jun 27, 2011 Started: Mar 31, 2008 Primary completion: Apr 30, 2011 Completion: Jun 30, 2011

This PHASE2/PHASE3 trial investigates Gastric Cancer and is currently completed. Japan Clinical Cancer Research Organization leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Japan Clinical Cancer Research Organization
  • Taiho Pharmaceutical Co., Ltd.
Data source: Japan Clinical Cancer Research Organization

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akita, Japan, Aomori, Japan, Asahikawa, Japan, Bunkyo-ku, Japan, Chiba, Japan, Chiyoda-ku, Japan, Fukui-shi, Japan, Fukuoka, Japan, Fukushima, Japan, Fukuyama, Japan and 52 more location s